Dashboard
Manage Tickers

ALDX


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-aldeyra-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Alde...
08/09/2024 10:05:10

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 ...

aldeyras-new-eye-drug-shows-positive-results-in-fda-approved-study-stock-jumps-over-30
Aldeyra's New Eye Drug Shows Positive Resu...
08/08/2024 16:30:05

Aldeyra Therapeutics announces successful results from its Phase 3 clinical trial of reproxalap. The results support a potentia...

aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-trial-for-reproxalap-ophthalmic-solution-in-treating-dry-eye-disease-statistically-superior-for-ocular-discomfort-nda-resubmission-anticipated-in-2024
Aldeyra Therapeutics Achieves Primary Endp...
08/08/2024 11:15:54

trading-halt-halted-at-65500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:00 a.m. ET - ...
08/08/2024 10:55:03

aldeyra-therapeutics-schedules-conference-call-and-webcast-on-thursday-august-8-2024-at-900-am-et-to-announce-top-line-results-from-the-phase-3-dry-eye-chamber-clinical-trial-of-reproxalap
Aldeyra Therapeutics Schedules Conference ...
08/07/2024 20:25:55

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, Augu...

hc-wainwright--co-reiterates-buy-on-aldeyra-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Alde...
08/02/2024 12:15:16

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 ...

aldeyra-therapeutics-wraps-up-phase-3-trial-enrollment-for-reproxalap-in-dry-eye-disease
Aldeyra Therapeutics Wraps Up Phase 3 Tria...
06/13/2024 11:04:23

Clinical Trial Results and Potential New Drug Application Resubmission Expected in the Second Half of 2024

aldeyra-therapeutics-enrolls-first-patient-in-phase-3-trial-designed-to-enable-potential-resubmission-of-new-drug-application-of-reproxalap-in-dry-eye-disease-clinical-results-and-potential-new-drug-application-submission-expected-in-2h-of-2024
Aldeyra Therapeutics Enrolls First Patient...
05/08/2024 11:14:47

oppenheimer-reiterates-outperform-on-aldeyra-therapeutics-maintains-10-price-target
Oppenheimer Reiterates Outperform on Aldey...
05/06/2024 11:46:39

Oppenheimer analyst Francois Brisebois reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Outperform and maintains $10 pri...

hc-wainwright--co-reiterates-buy-on-aldeyra-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Alde...
05/06/2024 10:38:45

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 ...

aldeyra-therapeutics-highlights-recent-preclinical-data-in-obesity-atopic-dermatitis-pain-and-alcoholic-hepatitis-and-announces-planned-pivotal-clinical-trial-in-retinitis-pigmentosa-at-2024-research--development-day
Aldeyra Therapeutics Highlights Recent Pre...
04/25/2024 11:26:39

aldeyra-therapeutics-and-2-other-stocks-under-5-insiders-are-buying
Aldeyra Therapeutics And 2 Other Stocks Un...
04/04/2024 10:23:06

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confide...

oppenheimer-upgrades-aldeyra-therapeutics-to-outperform-announces-10-price-target
Oppenheimer Upgrades Aldeyra Therapeutics ...
04/03/2024 13:58:41

Oppenheimer analyst Francois Brisebois upgrades Aldeyra Therapeutics (NASDAQ:ALDX) from Perform to Outperform and announces ...

hc-wainwright--co-reinstates-buy-on-aldeyra-therapeutics-announces-10-price-target
HC Wainwright & Co. Reinstates Buy on Alde...
04/02/2024 12:43:21

HC Wainwright & Co. analyst Matthew Caufield reinstates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and announces $10 ...

aldeyra-therapeutics-disclosed-clinical-development-plan-for-resubmission-of-new-drug-application-for-reproxalap-in-dry-eye-disease
Aldeyra Therapeutics Disclosed Clinical De...
03/28/2024 11:14:49

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
03/05/2024 21:31:07

aldeyra-therapeutics-reports-advancement-of-rasp-platform-in-systemic-and-retinal-inflammatory-diseases
Aldeyra Therapeutics Reports Advancement O...
01/04/2024 12:06:05

Based on positive biomarker results observed in adult cohort of Phase 2 clinical trial of ADX-629 in Sjögren-Larsson Syndrome, ...

Core News & Articles
On December 21, 2023, Aldeyra Therapeutics...
12/21/2023 21:19:12

As a result of the Exercise Period Extension, AbbVie may exercise the Option by delivering written notice to Aldeyra at any tim...

positive-news-for-skin-health-aldeyra-therapeutics-adx-629-achieves-key-milestones-in-atopic-dermatitis-study
Positive News For Skin Health: Aldeyra The...
12/19/2023 18:56:52

Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational R...

Core News & Articles
Market-Moving News for December 19th
12/19/2023 13:33:28

CGEN: 240% | Compugen Says It Will Be Eligible To Receive $10M Milestone Payment Upon Dosing Of First Patient In AstraZeneca Ph...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION